Triple Negative Breast Cancer


Cetin I., Topcul M.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.6, pp.2427-2431, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 15 Issue: 6
  • Publication Date: 2014
  • Doi Number: 10.7314/apjcp.2014.15.6.2427
  • Journal Name: ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2427-2431
  • Keywords: Triple negative breast cancer, poor prognosis, targeted therapy, ENDOTHELIAL GROWTH-FACTOR, FACTOR RECEPTOR, MOLECULAR SUBTYPES, RISK-FACTORS, STEM-CELLS, PROGNOSTIC VALUE, BASAL, CHEMOTHERAPY, CARCINOMA, SURVIVAL
  • Istanbul University Affiliated: Yes

Abstract

Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed. This mini-review focuses on discovery of new targets and drugs which might offer new hope for TNBC patients.